Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Reduced by State Street Corp

State Street Corp trimmed its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,156,426 shares of the specialty pharmaceutical company’s stock after selling 7,415 shares during the period. State Street Corp’s holdings in Supernus Pharmaceuticals were worth $67,237,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its stake in Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 398 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at $47,000. Innealta Capital LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 352 shares during the period. Finally, nVerses Capital LLC purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at $72,000.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 15,000 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the transaction, the senior vice president now owns 8,200 shares of the company’s stock, valued at approximately $303,236. This represents a 64.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jack A. Khattar sold 125,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. This trade represents a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,213 shares of company stock valued at $5,660,180. Insiders own 9.30% of the company’s stock.

Analysts Set New Price Targets

SUPN has been the topic of a number of research reports. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

SUPN opened at $36.22 on Wednesday. The company has a market capitalization of $2.00 billion, a PE ratio of 33.85 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37. The business has a 50-day moving average of $35.47 and a 200-day moving average of $32.11.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.29) earnings per share. On average, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.